المؤلفون: Verstovsek, Srdan, Mesa, Ruben A, Gotlib, Jason R, Gupta, Vikas, DiPersio, John F, Catalano, John V., Deininger, Michael Werner Nikolaus, Miller, Carole B, Silver, Richard T, Talpaz, Moshe, Winton, Elliott F, Harvey, Jimmie H, Arcasoy, Murat O, Hexner, Elizabeth Olson, Lyons, Roger M, Paquette, Ronald L, Raza, Azra, Jones, Mark, Kornacki, Deanna, Sun, Kang, Kantarjian, Hagop M

المصدر: Verstovsek , S , Mesa , R A , Gotlib , J R , Gupta , V , DiPersio , J F , Catalano , J V , Deininger , M W N , Miller , C B , Silver , R T , Talpaz , M , Winton , E F , Harvey , J H , Arcasoy , M O , Hexner , E O , Lyons , R M , Paquette , R L , Raza , A , Jones , M , Kornacki , D , Sun , K & Kantarjian , H M 2017 ....

مصطلحات موضوعية: JAK, Janus kinase, Myelofibrosis

وصف الملف: application/pdf

الإتاحة: https://doi.org/10.1186/s13045-017-0417-zTest
https://research.monash.edu/en/publications/d72c9643-3096-4626-837c-48fd0b458f2aTest
https://researchmgt.monash.edu/ws/files/245174330/92010409_oa.pdfTest
http://www.scopus.com/inward/record.url?scp=85013472843&partnerID=8YFLogxKTest

المؤلفون: Verstovsek, Srdan, Mesa, Ruben A., Gotlib, Jason, Gupta, Vikas, DiPersio, John F., Catalano, John V., Deininger, Michael W. N., Miller, Carole B., Silver, Richard T., Talpaz, Moshe, Winton, Elliott F., Harvey, Jimmie H., Arcasoy, Murat O., Hexner, Elizabeth O., Lyons, Roger M., Paquette, Ronald, Raza, Azra, Jones, Mark, Kornacki, Deanna, Sun, Kang, Kantarjian, Hagop

مصطلحات موضوعية: Myelofibrosis, JAK-STAT pathway, Clinical trials, Hematological oncology

العلاقة: https://doi.org/10.7916/D8CZ3KR4Test

الإتاحة: https://doi.org/10.7916/D8CZ3KR4Test

المؤلفون: Verstovsek, Srdan, Mesa, Ruben A., Gotlib, Jason, Levy, Richard S., Gupta, Vikas, DiPersio, John F., Catalano, John V., Deininger, Michael, Miller, Carole, Silver, Richard T., Talpaz, Moshe, Winton, Elliott F., Harvey, Jimmie H., Arcasoy, Murat O., Hexner, Elizabeth, Lyons, Roger M., Paquette, Ronald, Raza, Azra, Vaddi, Kris, Erickson‐viitanen, Susan, Sun, William, Sandor, Victor, Kantarjian, Hagop M.

مصطلحات موضوعية: Subgroups, Spleen Volume, Symptoms, Ruxolitinib, Myelofibrosis, Oncology and Hematology, Health Sciences

وصف الملف: application/pdf

العلاقة: Verstovsek, Srdan; Mesa, Ruben A.; Gotlib, Jason; Levy, Richard S.; Gupta, Vikas; DiPersio, John F.; Catalano, John V.; Deininger, Michael; Miller, Carole; Silver, Richard T.; Talpaz, Moshe; Winton, Elliott F.; Harvey, Jimmie H.; Arcasoy, Murat O.; Hexner, Elizabeth; Lyons, Roger M.; Paquette, Ronald; Raza, Azra; Vaddi, Kris; Erickson‐viitanen, Susan; Sun, William; Sandor, Victor; Kantarjian, Hagop M. (2013). "The clinical benefit of ruxolitinib across patient subgroups: analysis of a placeboâ controlled, Phase III study in patients with myelofibrosis." British Journal of Haematology 161(4): 508-516.; http://hdl.handle.net/2027.42/97529Test; British Journal of Haematology; Barosi, G., Mesa, R.A., Thiele, J., Cervantes, F., Campbell, P.J., Verstovsek, S., Dupriez, B., Levine, R.L., Passamonti, F., Gotlib, J., Reilly, J.T., Vannucchi, A.M., Hanson, C.A., Solberg, L.A., Orazi, A., Tefferi, A. & International Working Group for Myelofibrosis Research Treatment (IWG‐MR). ( 2008 ) Proposed criteria for the diagnosis of post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia, 22, 437 – 438.; Cervantes, F., Pereira, A., Esteve, J., Rafel, M., Cobo, F., Rozman, C. & Montserrat, E. ( 1997 ) Identification of ‘short‐lived’ and ‘long‐lived’ patients at presentation of idiopathic myelofibrosis. British Journal of Haematology, 97, 635 – 640.; Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Hehlmann, R., Hoffman, R., Kiladjian, J.J., Kroger, N., Mesa, R., McMullin, M.F., Pardanani, A., Passamonti, F., Vannucchi, A.M., Reiter, A., Silver, R.T., Verstovsek, S., Tefferi, A. & European Leukemia Net. ( 2011 ) Philadelphia‐negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Journal of Clinical Oncology, 29, 761 – 770.; Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J.F., Catalano, J.V., Deininger, M., Miller, C., Silver, R.T., Talpaz, M., Winton, E.F., Harvey, Jr J.H., Arcasoy, M.O., Hexner, E., Lyons, R.M., Paquette, R., Raza, A., Vaddi, K., Erickson‐Viitanen, S., Koumenis, I.L., Sun, W., Sandor, V. & Kantarjian, H.M. ( 2012 ) A double‐blind, placebo‐controlled trial of ruxolitinib for myelofibrosis. New England Journal of Medicine, 366, 799 – 807.; Verstovsek, S. ( 2009 ) Therapeutic potential of JAK2 inhibitors. Hematology/the Education Program of the American Society of Hematology, 636 – 642.; Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellstrom‐Lindberg, E., Tefferi, A. & Bloomfield, C.D. ( 2009 ) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937 – 951.; Vainchenker, W., Delhommeau, F., Constantinescu, S.N. & Bernard, O.A. ( 2011 ) New mutations and pathogenesis of myeloproliferative neoplasms. Blood, 118, 1723 – 1735.; Vainchenker, W., Dusa, A. & Constantinescu, S.N. ( 2008 ) JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Seminars in Cell and Developmental Biology, 19, 385 – 393.; Tefferi, A., Vaidya, R., Caramazza, D., Finke, C., Lasho, T. & Pardanani, A. ( 2011 ) Circulating interleukin (IL)‐8, IL‐2R, IL‐12, and IL‐15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. Journal of Clinical Oncology, 29, 1356 – 1363.; Tefferi, A. & Vardiman, J.W. ( 2008 ) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point‐of‐care diagnostic algorithms. Leukemia, 22, 14 – 22.; Tefferi, A. ( 2011 ) How I treat myelofibrosis. Blood, 117, 3494 – 3504.; Tefferi, A. ( 2000 ) Myelofibrosis with myeloid metaplasia. New England Journal of Medicine, 342, 1255 – 1265.; Second International Study of Infarct Survival (ISIS‐2) Collaborative Group. ( 1988 ) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS‐2. Lancet, 2, 349 – 360.; Passamonti, F., Cervantes, F., Vannucchi, A.M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E., Caramella, M., Maffioli, M., Pascutto, C., Lazzarino, M., Cazzola, M. & Tefferi, A. ( 2010 ) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG‐MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 115, 1703 – 1708.; Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T. & Carbone, P.P. ( 1982 ) Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology, 5, 649 – 655.; Nguyen, H. & Gotlib, J. ( 2012 ) Insights into the molecular genetics of myeloproliferative neoplasms. In: American Society of Clinical Oncology (ASCO) Education Book, pp. 411 – 418, Available at: http://www.asco.org/ASCOv2/Home/Education%20&%20Training/Educational%20Book/PDF%20Files/2012/zds00112000411.PDFTest.; Mesa, R.A., Niblack, J., Wadleigh, M., Verstovsek, S., Camoriano, J., Barnes, S., Tan, A.D., Atherton, P.J., Sloan, J.A. & Tefferi, A. ( 2007 ) The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet‐based survey of 1179 MPD patients. Cancer, 109, 68 – 76.; Gangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Van Dyke, D., Hanson, C., Wu, W., Pardanani, A., Cervantes, F., Passamonti, F. & Tefferi, A. ( 2011 ) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. Journal of Clinical Oncology, 29, 392 – 397.; Cuzick, J. ( 2005 ) Forest plots and the interpretation of subgroups. Lancet, 365, 1308.; Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J.T., Morra, E., Vannucchi, A.M., Mesa, R.A., Demory, J.L., Barosi, G., Rumi, E. & Tefferi, A. ( 2009 ) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113, 2895 – 2901.

الإتاحة: https://doi.org/10.1111/bjh.12274Test
http://hdl.handle.net/2027.42/97529Test

المؤلفون: Zhan, Huichun, Cardozo, Christopher, Raza, Azra

المصدر: British Journal of Haematology; May2013, Vol. 161 Issue 4, p471-483, 13p, 2 Diagrams, 2 Charts

مصطلحات موضوعية: BONE marrow cancer, MYELOPROLIFERATIVE neoplasms, MICRORNA, STEM cells, BLOOD platelets, HEMATOPOIESIS

المؤلفون: Bejanyan, Nelli, Tiu, Ramon V., Raza, Azra, Jankowska, Ania, Kalaycio, Matt, Advani, Anjali, Chan, Josephine, Saunthararajah, Yogen, Mooney, Lindsey, Maciejewski, Jaroslaw P., Sekeres, Mikkael A.

المصدر: Cancer (0008543X); Aug2012, Vol. 118 Issue 16, p3968-3976, 9p

مصطلحات موضوعية: MYELODYSPLASTIC syndromes treatment, THALIDOMIDE, ARSENIC trioxide, DEXAMETHASONE, VITAMIN C, GENETIC mutation, HUMAN cytogenetics

المؤلفون: Verstovsek, Srdan, Mesa, Ruben A., Gotlib, Jason, Levy, Richard S., Gupta, Vikas, DiPersio, John F., Catalano, John V., Deininger, Michael, Miller, Carole, Silver, Richard T., Talpaz, Moshe, Winton, Elliott F., Harvey, Jimmie H., Arcasoy, Murat O., Hexner, Elizabeth, Lyons, Roger M., Paquette, Ronald, Raza, Azra, Vaddi, Kris, Erickson-Viitanen, Susan

المصدر: New England Journal of Medicine. 3/1/2012, Vol. 366 Issue 9, p799-807. 9p. 3 Diagrams.

مصطلحات موضوعية: *PROTEIN kinase inhibitors, *MYELOFIBROSIS, *PLACEBOS, *SPLEEN, *ANEMIA, *THROMBOCYTOPENIA, *THERAPEUTICS